Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
2,006 people get PCYC articles and Market Currents by email alert.
Get email alerts on PCYC »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
PR Newswire (May 1, 2013)
-
PR Newswire (Apr 24, 2013)
-
-
-
PR Newswire (Mar 8, 2013)
-
-
PR Newswire (Mar 7, 2013)
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Pharmacyclics' Sale Of Blood Cancer Drug To J&J Is A Big DealEP Vantage • Sun, Dec 11, 2011 -
-
Is Pharmacyclics Eying China?ChinaBio Today • Sun, Feb 22, 2009 -
The Bull Case For Pharmacyclics (PCYC)• Thu, Dec 22, 2005
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Biotechnology In 2012: The Best Performing IndustryRyan's View • Tue, Dec 4, 2012 -
-
VIX - Options Volatility Sonar: Monday RecapErick McKitterick • Mon, Nov 5, 2012 -
-
-
-
Pharmacyclics' CEO Hosts ASH 2012 Recap Conference (Transcript)Wed, Dec 12, 2012
-
PR Newswire (May 1, 2013)
-
PR Newswire (Apr 24, 2013)
-
PR Newswire (Mar 8, 2013)
-
PR Newswire (Mar 7, 2013)
-
PR Newswire (Feb 14, 2013)
-
PR Newswire (Sep 5, 2012)
-
at Fox Business (Aug 24, 2012)
-
at Fox Business (Aug 22, 2012)
-
at Fox Business (Aug 22, 2012)
PCYC vs. ETF Alternatives
Company Description
We are a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. Our purpose is to create a profitable company by generating income from products we develop, license and... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 16, 1:39 PM Infinity Pharmaceuticals (INFI -20.5%) gets slammed by cautious comments out of JPMorgan today, saying that investors are "growing increasingly skittish" ahead of INFI's pending presentation at June's ASCO cancer conference. The company is expected to release Phase 1 clinical safety and tolerability data for IPI-145, its experimental leukemia drug, and while the investment bank predicts "a good showing," it may not be enough to outshine Gilead (GILD -2.3%), Pharmacyclics (PCYC -2.5%) or Roche (RHHBY.OB -0.6%). 3 Comments [Healthcare, On the Move]
- Monday, May 13, 1:10 PM Pharmacyclics (PCYC +9.5%) trades higher today after RBC Capital ups the shares to Outperform and raises its price target to $100 from $70. The firm cites optimism over a number of upcoming catalysts for its leukemia drug Ibrutnib, which is being jointly developed by PCYC and JNJ's Janssen Pharmaceuticals. 1 Comment [Healthcare, On the Move]
- Thursday, May 2, 6:24 AM Pharmacyclics (PCYC): Q1 EPS of -$0.40 misses by $0.23. Revenue of $2.85M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, May 1, 3:24 PM A number of biotechs are sharply lower amid rumors of a sizable Bio-fund going out of business and liquidating its positions. It's Ayer Capital Management according to sources, reports Adam Feuerstein. (PCYC -5.6%), (CLDX -4.9%), (NPSP -3.1%), (HALO -3.8%). 6 Comments [Healthcare, On the Move]
- Thursday, April 11, 10:29 AM Pharmacyclics (PCYC +1.7%) gets a bump higher this morning after announcing its Phase III clinical trial using Ibrutinib versus Chlorambucil to treat chronic lymphocytic leukemia and small lymphocyctic lymphoma has enrolled its fifth patient. The enrollment subsequently triggers a fourth $50M milestone payment obligation from JNJ's Janssen Biotech, who is collaborating with PCYC on Ibrutinib in oncology. On Monday, the drug was granted a 3rd "Breakthrough Therapy Designation" by the FDA. 1 Comment [Healthcare, On the Move]
- Monday, April 8, 7:19 AM Pharmacyclics' (PCYC) ibrutinib is granted a 3rd "Breakthrough Therapy Designation" by the FDA for treatment of certain patients with leukemia and lymphoma. (PR) 2 Comments [Healthcare]
- Monday, March 25, 2:23 PM Pharmacyclics (PCYC +2.3%) gains today on the back of positive comments out of Credit Suisse, saying they're excited about the multi-billion dollar potential of its lymphoma/leukemia drug ibrutinib, and see the recent weakness in the shares as a possible entry point. The firm has a target price of $90, which looks attainable with a number of positive catalysts on the horizon. Comment! [Healthcare, On the Move]
- Friday, March 8, 9:09 AM Pharmacyclics (PCYC) prices a previously announced public offering of 2.2M common shares, representing ~3.1% of common shares currently outstanding, at $94.20/share. After soaring 63% YTD, it's a smart and opportunistic capital raise, Jon Ogg writes. Shares -0.2% premarket. Comment! [Healthcare]
- Tuesday, February 19, 12:31 PM Pharmacyclics (PCYC -4.4%) slips after being downgraded to Market Perform at Leerink Swann on the back of its recent run. Leerink says that a number of key catalysts have already been realized, and further upside beyond its current valuation while possible, will require stronger sales numbers from ibrutinib than what's currently available. The firm raised its price target on the stock to $97 from $80. Comment! [Healthcare, On the Move]
- Thursday, February 14, 4:51 PM More on Pharmacyclics (PCYC): FQ2 beats on both sales and EPS expectations. Revenue for the quarter consisted primarily of $50M in milestone revenue due to hitting a clinical milestone in connection with it's collaboration and license agreement with Janssen Biotech, plus $5M of license revenue related to its license agreement with Novo Nordisk under which Novo acquired exclusive worldwide rights to its small molecule Factor VIIa inhibitor, PCI-27483, for a restricted disease indication outside of oncology. Comment! [Earnings]
- Thursday, February 14, 4:33 PM Pharmacyclics (PCYC): FQ2 EPS of $0.62 beats by $0.31. Revenue of $57.9M (-20% Y/Y) beats by $11M. (PR) Comment! [Healthcare, Earnings, Breaking News]
- Thursday, February 14, 12:10 AM Notable earnings after Thursday’s close: A, ACTV, BGS, BRCD, CBS, CRAY, ELLI, GG, HMA, KEG, KYAK, MXWL, NR, PCYC, QLIK, VVC, WRI Comment! [Earnings]
- Wednesday, February 13, 5:35 PM Notable earnings after Thursday’s close: A, ACTV, BGS, BRCD, CBS, CRAY, ELLI, GG, HMA, KEG, KYAK, MXWL, NR, PCYC, QLIK, VVC, WRI Comment! [Earnings]
- Wednesday, February 13, 8:26 AM The FDA grants "breakthrough" status to blood-cancer treatment ibrutinib, which is being developed by Pharmacyclics (PCYC +3.7%) and J&J (JNJ), for two rare types of lymphoma. The designation was created last year and could enable drug approval after just an expanded early stage study. The companies now plan to file for authorization of Ibrutinib by the end of the year. (PR) Comment! [Healthcare]
- Wednesday, January 30, 12:11 PM Pharmacyclics (PCYC +1%) moves higher in today's trading on an upgrade to Buy at TheStreet, citing the company's strong financials, "robust" revenue growth and a respectable return on equity. Comment! [Healthcare, On the Move]
- Tuesday, December 11, 2012, 11:41 AM Pharmacyclics (PCYC +5.5%) says that follow-up findings from an ongoing Phase II study suggest that its investigational oral agent ibrutinib resulted in "high and durable responses" and was generally well toleratedin patients with relapsed or refractory mantle cell lymphoma. Comment! [Healthcare, On the Move]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
whitehead1
$PCYC has given investors one of the highest return in last 5 years. What other stock can give us this kind of return? name names here. - View all 9 replies
-
whitehead1: what do you think of TC? that one I think has good future long term. Watching this one for a while. I like your AERL idea not too much PPHM
-
DaLatin: I buy PPHM every time it goes under a buck. Then I set a gtc sale in for a double and wait. Can't remember how many times it's hit.A bunch !
-
Joshua Hayes
NASDAQ Stalls as Volume Finishes Higher http://bit.ly/VRUXCL $KORS $INVN $AAPL $PCYC $NTGR $BWLD - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
freefdawatchlist
http://stks.co/kDzg Bearish call on $BMRN, 3k patient cannot generate 775 million in 2015. Its a sell with PT of 40. $PCYC" $BMRN - View all 0 replies
LATEST REPLIES
-
whitehead1
$PCYC has given investors one of the highest return in last 5 years. What other stock can give us this kind of return? name names here. - View all 9 replies
-
whitehead1: what do you think of TC? that one I think has good future long term. Watching this one for a while. I like your AERL idea not too much PPHM
-
DaLatin: I buy PPHM every time it goes under a buck. Then I set a gtc sale in for a double and wait. Can't remember how many times it's hit.A bunch !
-
- View all 1 replies
-
-
- View all 1 replies
-
-
- View all 1 replies
-
-
- View all 4 replies
-
Iron Hamster: Any idea why SCL is dropping? Everything I'm reading says it's a buy and it's too early for profit taking, yet it's down on an up day. -
-
- View all 2 replies
-
emburns: Should have picked up some - crossing 60 probably hit stop orders and caused that drop. Easy 4% trade.
-
Ryan Mallory: that was my thoughts happened a few weeks ago and the same thing happened - which is why i jumped on it.
-
- View all 2 replies
-
-
-
- View all 5 replies
-
tradingblues1: PCYC given an $80 price target by Bream Murray!!!! Thats more than double PCYC opened up at today! http://bit.ly/MiLEkL
-
-
- View all 1 replies
-
-
- View all 1 replies
-
-
- View all 6 replies
-
-
